



IMMUNOLOGICAL CONTROL OF  $\beta$ -AMYLOID LEVELS IN VIVO

Abstract of the Disclosure

Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a  $\beta$ -amyloid epitope.

Also disclosed are methods for inhibiting the formation of  $\beta$ -amyloid plaques in the brain of a human, or promoting the

disaggregation of a preformed  $\beta$ -amyloid plaque. Such methods recite the administration of a bispecific antibody.

20120 0032950